Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Hilleman

Showing results (11-20 of 66) with videos related to

Pageof 7
Sort By:
Expert Opinion on Pharmacotherapy|June 30, 2006
Pharmacoeconomic considerations with statin therapyKatie M Speidel, Daniel E Hilleman
Expert Opinion on Pharmacotherapy|February 28, 2002
The economic impact of chronic obstructive pulmonary diseaseMichele A Faulkner, Daniel E Hilleman
Clinical Medicine Insights. Cardiology|February 12, 2014
Potential benefits of icosapent ethyl on the lipid profile: case studiesDaniel E Hilleman, Mark A Malesker
Pharmacotherapy|September 2, 2004
Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?Daniel E Hilleman, B Daniel Lucas
Journal of Critical Care|February 4, 2012
Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patientsMark A Malesker, Daniel E Hilleman
P & T : a Peer-Reviewed Journal for Formulary Management|January 7, 2014
Overview of omega-3 Fatty Acid therapiesJ Chris Bradberry, Daniel E Hilleman
Future Cardiology|January 16, 2024
Lipid lowering therapy: implications of recent clinical trialsJames M Backes, Daniel E Hilleman
Postgraduate Medicine|January 17, 2013
Novel strategies for managing dyslipidemia: treatment beyond statinsHua Ling, Tammy L Burns, Daniel E Hilleman
Journal of Pharmacy Practice|January 24, 2019
Knowledge, Perceptions, and Patterns of Fish Oil Use in Cardiac PatientsDaniel E Hilleman, Robyn Teply, Kathleen A Packard
Cardiovascular Therapeutics|December 21, 2013
An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterolHua Ling, Tammy L Burns, Daniel E Hilleman
Pageof 7

Showing results (11-20 of 66) with videos related to

Sort By:
Pageof 7
Expert Opinion on Pharmacotherapy|June 30, 2006
Pharmacoeconomic considerations with statin therapyKatie M Speidel, Daniel E Hilleman
Expert Opinion on Pharmacotherapy|February 28, 2002
The economic impact of chronic obstructive pulmonary diseaseMichele A Faulkner, Daniel E Hilleman
Clinical Medicine Insights. Cardiology|February 12, 2014
Potential benefits of icosapent ethyl on the lipid profile: case studiesDaniel E Hilleman, Mark A Malesker
Pharmacotherapy|September 2, 2004
Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction?Daniel E Hilleman, B Daniel Lucas
Journal of Critical Care|February 4, 2012
Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patientsMark A Malesker, Daniel E Hilleman
P & T : a Peer-Reviewed Journal for Formulary Management|January 7, 2014
Overview of omega-3 Fatty Acid therapiesJ Chris Bradberry, Daniel E Hilleman
Future Cardiology|January 16, 2024
Lipid lowering therapy: implications of recent clinical trialsJames M Backes, Daniel E Hilleman
Postgraduate Medicine|January 17, 2013
Novel strategies for managing dyslipidemia: treatment beyond statinsHua Ling, Tammy L Burns, Daniel E Hilleman
Journal of Pharmacy Practice|January 24, 2019
Knowledge, Perceptions, and Patterns of Fish Oil Use in Cardiac PatientsDaniel E Hilleman, Robyn Teply, Kathleen A Packard
Cardiovascular Therapeutics|December 21, 2013
An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterolHua Ling, Tammy L Burns, Daniel E Hilleman
Pageof 7